CICERI, PAOLA
 Distribuzione geografica
Continente #
EU - Europa 5.111
AS - Asia 4.955
NA - Nord America 4.624
SA - Sud America 449
AF - Africa 104
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 6
Totale 15.273
Nazione #
US - Stati Uniti d'America 4.468
GB - Regno Unito 1.771
CN - Cina 1.520
SG - Singapore 1.508
IT - Italia 1.012
DE - Germania 529
HK - Hong Kong 440
RU - Federazione Russa 391
VN - Vietnam 378
BR - Brasile 315
BD - Bangladesh 306
SE - Svezia 296
FR - Francia 254
IN - India 221
NL - Olanda 193
FI - Finlandia 160
IE - Irlanda 124
TR - Turchia 105
KR - Corea 103
CA - Canada 89
JP - Giappone 84
ID - Indonesia 78
DK - Danimarca 58
UA - Ucraina 57
AR - Argentina 50
ES - Italia 49
CI - Costa d'Avorio 39
BE - Belgio 37
MX - Messico 37
PL - Polonia 35
EU - Europa 29
TW - Taiwan 28
GR - Grecia 26
AT - Austria 23
CO - Colombia 23
IQ - Iraq 23
AU - Australia 20
IR - Iran 20
EC - Ecuador 19
TH - Thailandia 17
ZA - Sudafrica 17
CH - Svizzera 16
PK - Pakistan 15
PE - Perù 14
CL - Cile 13
SA - Arabia Saudita 12
RO - Romania 11
BH - Bahrain 10
PH - Filippine 10
KE - Kenya 9
MA - Marocco 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
PT - Portogallo 8
EG - Egitto 7
NO - Norvegia 7
RS - Serbia 7
VE - Venezuela 7
AL - Albania 6
CZ - Repubblica Ceca 6
IL - Israele 6
MY - Malesia 6
NP - Nepal 6
CY - Cipro 5
DO - Repubblica Dominicana 5
HU - Ungheria 5
LT - Lituania 5
PS - Palestinian Territory 5
PY - Paraguay 5
TN - Tunisia 5
AZ - Azerbaigian 4
DZ - Algeria 4
MK - Macedonia 4
NG - Nigeria 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
A2 - ???statistics.table.value.countryCode.A2??? 3
CR - Costa Rica 3
HN - Honduras 3
JO - Giordania 3
KW - Kuwait 3
KZ - Kazakistan 3
LU - Lussemburgo 3
MO - Macao, regione amministrativa speciale della Cina 3
SI - Slovenia 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CG - Congo 2
CU - Cuba 2
GE - Georgia 2
GT - Guatemala 2
HR - Croazia 2
JM - Giamaica 2
LB - Libano 2
MD - Moldavia 2
MM - Myanmar 2
OM - Oman 2
PR - Porto Rico 2
QA - Qatar 2
Totale 15.272
Città #
Southend 1.631
Singapore 848
Ashburn 546
Hong Kong 394
Milan 380
Dallas 358
San Jose 344
Chandler 330
Beijing 241
Council Bluffs 173
Los Angeles 154
Santa Clara 152
Fairfield 141
Hefei 141
Princeton 132
Dublin 117
Seattle 116
Ann Arbor 115
Wilmington 115
Ho Chi Minh City 113
Frankfurt am Main 109
New York 103
Helsinki 99
Hanoi 94
Lauterbourg 88
Dearborn 87
Bengaluru 86
Guangzhou 81
Moscow 81
Munich 76
Boardman 70
Shanghai 63
Buffalo 62
Rome 62
Houston 59
Woodbridge 58
Jakarta 55
Des Moines 48
Nanjing 48
Tokyo 48
Chicago 42
Seoul 41
Phoenix 40
Abidjan 39
Jinan 38
São Paulo 38
The Dalles 38
Toronto 38
Istanbul 37
Redmond 35
Berlin 32
Cambridge 32
Mountain View 31
Brussels 30
Columbus 30
Cangzhou 29
Fuzhou 26
Tianjin 26
Wuhan 26
Changsha 25
Turin 25
Jacksonville 23
Redwood City 23
Warsaw 23
Shenyang 22
Dong Ket 21
Boston 20
Hangzhou 20
Shenzhen 20
Eitensheim 19
Hanover 19
Lappeenranta 19
Bologna 18
Düsseldorf 18
Kent 18
Sakarya 18
Bogotá 16
Naples 16
Quanzhou 16
Zhengzhou 16
Athens 15
Buenos Aires 15
Nanchang 15
Bangkok 14
Florence 14
Haiphong 14
Hebei 14
Salt Lake City 14
Segrate 14
Somerville 14
Stockholm 14
Turku 14
Vienna 14
Atlanta 13
Central District 13
Guayaquil 13
Nuremberg 13
Andover 12
Bari 12
Genoa 12
Totale 9.354
Nome #
Iron biology 633
Vitamin D receptor activation and prevention of arterial ageing [Reprint of] 342
Lanthanum Prevents High Phosphate-Induced Vascular Calcification by Preserving Vascular Smooth Muscle Lineage Markers 327
Cardiovascular disease in dialysis patients 313
The effect of paricalcitol on vascular calcification and cardiovascular disease in uremia : beyond PTH control 310
Le alterazioni metaboliche del paziente nefropatico 307
The key role of phosphate on vascular calcification 303
Importance of vitamin D receptor activation in clinical practise 300
The combination of lanthanum chloride and the calcimimetic calindol delays the progression of vascular smooth muscle cells calcification 272
Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis 261
Growth Differentiation Factor 15 (GDF-15) Levels Associate with Lower Survival in Chronic Kidney Disease Patients with COVID-19 256
Vascular calcification in chronic kidney disease : an update 255
Vitamin K in Chronic Kidney Disease 247
Effetti cardioprotettivi della vitamina D nei pazienti con malattia renale cronica allo stadio 3-5 non in dialisi 242
High-phosphate induced vascular calcification is reduced by iron citrate through inhibition of extracellular matrix osteo-chondrogenic shift in VSMCs 242
La vitamina D nei pazienti con malattia renale cronica 236
Pathophysiology of calcium and phosphate metabolism impairment in Chronic Kidney Disease 233
A new in vitro model to delay high phosphate-induced vascular calcification progression 230
Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation 227
Pathogenesis and treatment of vascular calcification in CKD 221
Vascular calcification in chronic kidney disease : a changing scenario 220
The Calcimimetic Calindol Prevents High Phosphate-Induced Vascular Calcification by Upregulating Matrix GLA Protein 219
Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease 218
Prevenzione e trattamento dell’iperparatiroidismo secondario nel paziente con malattia renale cronica allo stadio 3-5 non in dialisi 218
Phosphate control in peritoneal dialysis 217
Restoring the physiology of vitamin d receptor activation and the concept of selectivity 216
Early aging and premature vascular aging in chronic kidney disease 208
Covid-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors 208
Osteonectin (SPARC) Expression in Vascular Calcification : In Vitro and Ex Vivo Studies 204
High-phosphate Causes Endothelial Extracellular Matrix Calcification by Inducing Endothelial Cell Mesenchymal Transition and Osteoblastic Differentiation 203
Vitamin D receptor activation and prevention of arterial ageing 203
Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease 202
Role of sodium in intracellular calcium elevation and leukotriene B4 formation by agonist activated human neutrophils 199
Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency 198
Klotho: a potential therapeutic target in aging and neurodegeneration beyond chronic kidney disease—a comprehensive review from the ERA CKD-MBD working group 194
Iron citrate reduces high-phosphate induced vascular calcification by inhibiting osteo-chondrogenic shift of extracellular matrix in VSMCs 194
RAASi, MRA and FGF-23 in CKD progression: the usual suspects? 190
Iron citrate blocks the progression of calcium deposition by reverting apoptosis and autophagy in VSMCS 182
Secondary Hyperparathyroidism in End-Stage Renal Disease : No Longer a Matter for Surgeons? 179
Covid-19 Pandemic Era: Is It Time To Promote Home Dialysis And Peritoneal Dialysis? 178
Future treatment of vascular calcification in chronic kidney disease 177
Calcifediol to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease 177
Transforming the frail and elderly patient into an Iron Man: how to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease 174
Iron citrate reduces high phosphate-induced vascular calcification by inhibiting apoptosis 173
Uremic Patients with Increased Vascular Calcification Score Have Serum with High Calcific Potential : Role of Vascular Smooth Muscle Cell Osteoblastic Differentiation and Apoptosis 169
Vitamin D Receptor (VDR) and progression of kidney failure 165
Osteoporosis, bone mineral density and CKD-MBD: treatment considerations 162
Phosphate in chronic kidney disease progression 157
The Cardiovascular Burden in End-Stage Renal Disease 154
Heterogeneous platelet-activating factor (PAF) receptors and calcium increase in platelets and macrophages 150
Cardiovascular calcifications in kidney transplant recipients 149
Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study 148
Current Therapy in CKD Patients Can Affect Vitamin K Status 147
SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease 145
Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy 141
Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, Current treatments and investigational drugs 140
Choice of the Dialysis Modality: Practical Considerations 133
Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction 133
Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study 127
The Role of Uremic Retention Solutes in the MIA Syndrome in Hemodialysis Subjects 125
Levels of Cell-Free DNA in Kidney Failure Patients before and after Renal Transplantation 122
Vitamin D: are all compounds equal? 121
Efficacy and safety of etelcalcetide in hemodialysis patients with moderate to severe secondary hyperparathyroidism 120
Nutritional vitamin D in CKD: Should we measure ? Should we treat? 119
"Inflammasome" Activity in Dialysis Patients: The Need to Go beyond Membrane Separation Mechanisms 115
Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly 115
Angiopoietin as A Novel Prognostic Marker in Kidney Disease 114
Measuring FGF23 in clinical practice: dream or reality? 112
Kynurenine Promotes Phosphate-Induced Endothelial Calcification via Endothelial-to-Mesenchymal Transition, Osteoblastic Differentiation and AhR Activation 110
Effect of iron citrate on matrix and simil-osteoblastic differentiation in high phosphatetreated vascular smooth muscle cells 110
Calciphylaxis after Kidney Transplantation: a rare but life-threatening disorder 109
Intrauterine life to adulthood: a potential risk factor for chronic kidney disease 106
A roadmap to parathyroidectomy for kidney transplant candidates 106
Patient-specific multifactorial mortality risk assessment using classification and regression tree analysis in the context of ambulatory blood pressure monitoring 103
Phosphate binders in dialysis : better satisfied than sorry 103
From Physicochemical Classification to Multidimensional Insights: A Comprehensive Review of Uremic Toxin Research 102
High glucose enhances inflammation-driven platelet adhesion to endothelial cells in vitro 100
Calcimimetics and vascular calcification 100
The emerging role of iron in heart failure and vascular calcification in CKD 100
Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins 100
An update on tenapanor to treat hyperphosphatemia 94
Do we need new phosphate binders in dialysis? 90
The pathophysiology and management of vascular calcification in chronic kidney disease patients 88
MCO Membranes and FGF-23: Advancing Dialysis Strategies for Better Outcomes? 87
Ectopic Calcification in Uremia: Where Do We Stand? 74
Hyperphosphatemia : a novel risk factor for mortality in chronic kidney disease 72
The role of activin : the other side of chronic kidney disease-mineral bone disorder? 71
Vitamin D receptor activation and prevention of arterial aging 64
Uremic Toxin‐Driven Vascular Calcification in Chronic Kidney Disease: Molecular Pathways and Integrated Phenotypes 63
The Role of Vitamin K in Vascular Calcification 62
Critical evaluation of therapeutic targeting in chronic kidney disease: where do we stand 5 years on? 36
Apoptotic Bodies in Kidney Disease: Orchestrators of Inflammation, Fibrosis, and Repair 7
null 6
Vascular Calcification in Advanced Chronic Kidney Disease: Epidemiology, Pathophysiology, and Treatment 1
ENDOCRINE AND METABOLIC ALTERATIONS IN AGING PLWH WITH LOW BONE MINERAL DENSITY 1
Totale 15.856
Categoria #
all - tutte 42.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.941


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202196 0 0 0 0 0 0 0 0 0 0 0 96
2021/2022967 113 62 58 56 82 58 72 43 76 97 67 183
2022/20231.165 151 124 107 111 109 234 25 47 120 16 75 46
2023/2024934 64 73 72 55 212 59 47 40 17 71 93 131
2024/20252.475 92 209 43 230 207 87 49 188 144 337 301 588
2025/20266.242 675 442 702 549 549 398 853 266 605 381 681 141
Totale 15.856